ImmunoGen (IMGN) Research Coverage Started at HC Wainwright
HC Wainwright assumed coverage on shares of ImmunoGen (NASDAQ:IMGN) in a report issued on Wednesday, January 31st, Marketbeat.com reports. The firm set a “buy” rating on the biotechnology company’s stock.
Several other equities research analysts have also commented on IMGN. Jefferies Group restated a “buy” rating and issued a $9.00 price objective on shares of ImmunoGen in a research note on Thursday, October 12th. Zacks Investment Research upgraded ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 price objective for the company in a research note on Tuesday, October 31st. Cantor Fitzgerald restated a “hold” rating and issued a $5.00 price objective on shares of ImmunoGen in a research note on Friday, November 3rd. Finally, BidaskClub upgraded ImmunoGen from a “hold” rating to a “buy” rating in a research note on Thursday, January 18th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. ImmunoGen currently has an average rating of “Buy” and an average target price of $7.83.
ImmunoGen (NASDAQ IMGN) traded down $0.13 during trading hours on Wednesday, hitting $8.88. The stock had a trading volume of 2,814,247 shares, compared to its average volume of 3,148,263. The company has a debt-to-equity ratio of -0.03, a current ratio of 2.81 and a quick ratio of 2.78. The stock has a market cap of $1,192.90, a price-to-earnings ratio of -6.83 and a beta of 2.50. ImmunoGen has a 52-week low of $2.31 and a 52-week high of $10.04.
ILLEGAL ACTIVITY WARNING: This report was published by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/02/02/immunogen-imgn-receives-new-coverage-from-analysts-at-hc-wainwright.html.
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.